Study protocol to assess polypharmacy and comorbidities in lung cancer

Author:

Pluchart HélèneORCID,Bailly SébastienORCID,Fauconnier JérômeORCID,Delafosse Patricia,Chanoine Sébastien,Dumas Isabelle,Bedouch Pierrick,Toffart Anne-Claire

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference18 articles.

1. Comorbidities in the management of patients with lung cancer;Leduc;Eur Respir J,2017

2. Comorbidity and survival in lung cancer patients;Islam;Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. juill,2015

3. Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer;Edwards;Cancer. 1 mai,2014

4. Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, et al. SEER Cancer Statistics Review, 1975-2015, National Cancer Institute [Internet]. [cité 30 juill 2018]. Disponible sur: https://seer.cancer.gov/csr/1975_2015/sections.html

5. Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer;Nightingale;J Clin Oncol Off J Am Soc Clin Oncol. 1 mai,2015

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3